Day One Biopharmaceuticals (NYSE: DAWN) — Perfil da empresa, notícias e dados financeiros
Day One Biopharmaceuticals develops targeted cancer therapies focused on precision medicine.
Day One Biopharmaceuticals
Day One Biopharmaceuticals (NASDAQ:DAWN) is a dynamic player in the healthcare sector, focused on developing targeted therapies for patients battling cancer. The company is passionate about driving innovations that can lead to more effective treatments for oncology patients, particularly those with limited options available. At the core of its mission, Day One seeks to leverage cutting-edge science and research to bring new, life-saving drugs to market. With a keen focus on precision medicine, its projects aim to match patients with the therapies most likely to benefit them based on the specific genetic characteristics of their tumors. The objective is clear: to transform the way cancer is treated, one patient at a time, by delivering promising new therapies as quickly and safely as possible.
Resumo
Operações
Produtos e/ou serviços de Day One Biopharmaceuticals
- Tovorafenib (DAY101) - A potential first-in-class, once-weekly, brain-penetrant, oral pan-RAF inhibitor for the treatment of pediatric low-grade glioma.
- Pimasertib - An orally bioavailable MEK inhibitor aimed at advanced solid tumors with specific mutations.
- Clinical trial collaborations - Collaborating with leading institutions and companies to accelerate the development of novel therapies for cancer.
- Research in MAPK pathway - Focused on unraveling the mitogen-activated protein kinase (MAPK) pathway to identify therapeutic targets for cancer treatment.
- Pediatric glioma program - Dedicated to developing treatments specifically for pediatric patients suffering from glioma.
- Patient advocacy and support programs - Offering resources and support to patients and families affected by cancer, emphasizing those with pediatric and rare cancers.
equipe executiva do Day One Biopharmaceuticals
- Dr. Jeremy Bender M.B.A., Ph.D.CEO, President & Director
- Mr. Charles N. York II, M.B.A.COO & CFO
- Mr. Adam Dubow J.D.General Counsel, Chief Compliance Officer & Secretary
- Mr. John Stubenrauch Ph.D.Chief Technology Officer
- Dr. Heather Adkins Huet Ph.D.Chief Scientific Officer
- Mr. Joey PerroneSenior Vice President of Finance & Investor Relations
- Ms. Jaa RobersonChief People Officer
- Dr. Davy Chiodin Ph.D., Pharm.D.Chief Development Officer
- Ms. Lauren Merendino M.B.A.Chief Commercial Officer
- Dr. Elly Barry M.D.Chief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Day One Biopharmaceuticals, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 158,2 mi | -127,8 mi | -107,3 mi | |
| 131,2 mi | -217,3 mi | -95,5 mi | |
| 0 | -206,1 mi | -188,9 mi | |
| 0 | -146,9 mi | -132,2 mi |